Systemic Lupus Erythematosus – Geographic Focus: China – China In-Depth – Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs or systems in the body. The treatment goals of physicians who manage SLE patients differ depending on the individual patient’s disease severity. BiologicsGSK’s Benlysta and RemeGen’s Tetasipare usually used in later lines of treatment, most commonly in moderate to severe SLE patients who are not adequately managed with conventional therapies (e.g., hydroxychloroquine, corticosteroids, immunosuppressants) or as steroid-sparing agents in patients receiving high doses of corticosteroids. China’s SLE therapy market will experience rapid growth over the 2023-2033 forecast period with the launch of several novel targeted therapies including Novartis’s ianalumab, BMS’s deucravacitinib, AstraZeneca’s anifrolumab, Biogen’s litifilimab (BIIB059), and Mabworks’ MIL62. In this report, we explore how unmet need, pricing, coverage, and regulatory reforms in China will likely impact the success of current and future players in this highly lucrative market.
Questions answered
- What is the diagnosed prevalence of SLE, and how are these patients treated today? Do treatment management strategies differ between urban and rural China?
- What are the most important drugs for the treatment of patients without active renal disease and lupus nephritis (LN), and why? What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of SLE?
- What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
Product description
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Geography: China
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 rheumatologists and nephrologists
Epidemiology: Number of diagnosed and drug-treated SLE patients in China, segmented by nonrenal SLE and lupus nephritis
Forecast: 10-year, annualized, drug-level sales and patient share of key SLE therapies through 2033, based on primary and secondary market research to formulate bottom-up assumptions
Emerging therapies: Phase 3/PR: 5+ drugs.
NEW: China In-Depth reports include a custom drug modeler. This tool enables clients to input their own assumptions for a drug and forecast three scenarios that can be directly compared with Clarivate’s projections for drugs included in the patient-based market forecast. To access the tool, download the Market Forecast Dashboard file on the Insights Platform.
